Literature DB >> 10447095

Hypothalamic NPY status during positive energy balance and the effects of the NPY antagonist, BW 1229U91, on the consumption of highly palatable energy-rich diet.

P S Widdowson1, L Henderson, L Pickavance, R Buckingham, M Tadayyon, J R Arch, G Williams.   

Abstract

We have studied the hypothalamic activity of the neuropeptide Y (NPY) system in dietary-induced obese male Wistar rats and examined whether the NPY antagonist, BW1229U91, can inhibit the hyperphagia during positive energy balance associated with feeding rats an energy-rich, highly palatable diet. Rats given a highly palatable, high-fat diet became obese after 8 weeks and exhibited hyperinsulinemia and hyperleptinemia, as compared to lean rats fed on standard pellet laboratory diet. Hypothalamic NPY mRNA concentrations were significantly reduced by approximately 70% in dietary-obese rats compared with lean controls, and the former were hypersensitive to intracerebroventricular injections of NPY, possibly as a result of NPY receptor up-regulation. Intracerebroventricular injections of BW 1229U91, that inhibits food intake in starved rats, did not alter food intake in either control or obese rats fed either standard pellet diet or the highly palatable diet, respectively. We conclude that dietary-obese rats have underactive hypothalamic NPYergic neurons compared to lean controls, possibly as a result of increased plasma concentrations of leptin and/or insulin that directly inhibit the NPY neuronal activity. The lack of effect of BW1229U91 on the increased caloric intake of dietary-obese rats suggests that the hyperphagia is not NPY-driven and supports the data indicating reduced synaptic activity of the hypothalamic NPY system.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10447095     DOI: 10.1016/s0196-9781(99)00044-3

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  4 in total

Review 1.  Drug treatment of obesity: from past failures to future successes?

Authors:  P Collins; G Williams
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

Review 2.  Neuropeptide Y in normal eating and in genetic and dietary-induced obesity.

Authors:  B Beck
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

3.  Effect of dietary fatty acid composition on food intake, triglycerides, and hypothalamic peptides.

Authors:  Jessica R Barson; Olga Karatayev; Valeriya Gaysinskaya; Guo-Qing Chang; Sarah F Leibowitz
Journal:  Regul Pept       Date:  2011-09-06

Review 4.  Neuropeptide and sigma receptors as novel therapeutic targets for the pharmacotherapy of depression.

Authors:  Konstantinos A Paschos; Stavroula Veletza; Ekaterini Chatzaki
Journal:  CNS Drugs       Date:  2009-09       Impact factor: 5.749

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.